Lithium Australia and Pilbara Minerals Join Forces

|

Published 28-JUN-2016 10:02 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Lithium Australia (ASX:LIT) and the $595 million capped Pilbara Minerals (ASX:PLS) have agreed to establish a joint venture. The JV is subject to a series of feasibility studies and testwork programs and will investigate the suitability of LIT’s SileachTM process to produce high-value lithium carbonate.

Known as the SJV, the partnership will be a 50/50 collaboration that tests concentrates sourced from Pilbara’s Pilgangoora Project.

SJV’s goal is to be a lowest quartile lithium carbonate producer by commercialising the SileachTM process and investigating the viability of jointly developing a lithium conversion facility.

The facility would potentially source spodumene concentrate from Pilbara’s 100%-owned Pilgangoora Lithium-Tantalum Project.

This could then be used to process feed from other Pilbara lithium mineral producers by agreement of the joint venture partners.

LIT Managing director, Mr Adrian Griffin says, “The agreement with Pilbara Minerals is a very important step towards Lithium Australia’s goal of becoming a lowest cost quartile lithium carbonate producer.

“Successfully combining PLS’ Pilgangoora spodumene concentrates with the low-energy Sileach process has the potential to add enormous value to both parties and may allow the SJV to deal directly with lithium chemical consumers, including the battery manufacturers.

“This is a great deal for LIT, PLS and for Western Australia’s burgeoning lithium processing industry.”

The agreement between LIT and follows successful lithium extraction from spodumene by ANSTO Minerals (a division of the Australian Nuclear Science and Technology Organisation) in which lithium extractions of greater than 90% were achieved in as little as four hours.

The SJV will see LIT cover the cost of pilot testing, while PLS supplied the spodumene for testing. Operational costs will be split 50/50.

Unlike conventional lithium recovery from spodumene, the SileachTM process does not require roasting, resulting in a much more energy efficient process and potential to compete with the world’s lowest cost producers.

Lithium’s path to commercialisation

The SileachTM process has been successfully tested in the course of bench testing at a number of laboratories.

Most recently testing of concentrates from Pilgangoora, and other spodumene sources, have provided sufficient knowledge to consider pilot testing at the ANSTO Minerals facility in New South Wales.

Testing will start shortly and is the second step in the SJV’s attempt to de-risk the path to commercial production.

Lithium Australia has a clear path to commercial production

Should testing at ANSTO Minerals be successful, the SJV may then decide to start construction of a larger-scale pilot plant, with the ability to recover costs through the production of commercial lithium chemicals and by-products.

Operation of the larger-scale pilot facility will be a milestone step in commercialisation of the SileachTM process, and will be used do demonstrate the viability of the process for funding purposes.

Definitive Feasibility Study

Data generated from operating the large-scale pilot plant will be used to complete engineering design and feasibility investigations for the construction of a full-scale commercial SileachTM processing plant. The Feasibility Study will be managed by LIT.

Commercial SileachTM processing plant

In the event of a positive outcome of the Definitive Feasibility Study, the SJV will advance to commercial production, including finance and construction, on a 50/50 basis. The key terms of this joint venture will include:

  • LIT will be the first manager of the SJV;
  • PLS to provide feed to the SJV on a priority basis

The successful development of a commercial hydrometallurgical process to recover lithium from spodumene would place the SJV at the leading edge of the lithium industry, by providing the potential to be much more energy efficient. Reduction of energy consumption, together with the potential to recover valuable by-product credits, may provide cost efficiencies which were not previously possible.

tags

LITHIUM


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X